Company
Seneca Therapeutics
Developing the most revolutionary oncolytic immunotherapeutic candidates to provide advanced targeted treatments for solid cancer
Also known as Seneca Therapeutics, Inc.
- Status
- Operatingas of 2026-09-18Source (opens in a new tab)
- Legal name
- Seneca Therapeutics, Inc.
Claim, correct or request removal
Record updated 18 September 2026
About
Seneca Therapeutics was founded to capitalize on the profound tumor specificity of SVV and further the development of SVV-001 in several upcoming clinical trials and the creation and testing of armed derivatives selectively expressing gene product(s) that are inserted into the genome of SVV-001 that create additional anti-tumor effects.
Funding snapshot
- Total raised
- $3.9MSum of rounds, as of 2026-09-18Source (opens in a new tab)
- Latest round
- Series B, $3.9M2025-09-05
Funding rounds
- Series B
- $3.9M2025-09-05, Company stated
Loading relationship preview